Literature DB >> 18268546

Angiogenesis as a strategic target for ovarian cancer therapy.

Whitney A Spannuth1, Anil K Sood, Robert L Coleman.   

Abstract

Angiogenesis is a complex and highly regulated process that is crucial for tumor growth and metastasis. Insights into the molecular mechanisms of tumor angiogenesis have led to the identification of potential angiogenic targets and the development of novel antivascular agents. Many of these agents are being evaluated in clinical trials and have shown promising antitumor activity. This Review highlights the results of the latest clinical studies of antivascular agents in ovarian cancer and discusses the challenges and opportunities for future clinical trials.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18268546     DOI： 10.1038/ncponc1051

Source DB:  PubMed          Journal:  Nat Clin Pract Oncol        ISSN： 1743-4254


  54 in total

1.  Targeted gene silencing using RGD-labeled chitosan nanoparticles.

Authors:  Hee Dong Han; Lingegowda S Mangala; Jeong Won Lee; Mian M K Shahzad; Hye Sun Kim; Deyu Shen; Eun Ji Nam; Edna M Mora; Rebecca L Stone; Chunhua Lu; Sun Joo Lee; Ju Won Roh; Alpa M Nick; Gabriel Lopez-Berestein; Anil K Sood
Journal:  Clin Cancer Res       Date:  2010-06-10       Impact factor: 12.531

Review 2.  Biobehavioral factors and cancer progression: physiological pathways and mechanisms.

Authors:  Susan K Lutgendorf; Anil K Sood
Journal:  Psychosom Med       Date:  2011-10-21       Impact factor: 4.312

3.  Bridging the gap between cytotoxic and biologic therapy with metronomic topotecan and pazopanib in ovarian cancer.

Authors:  William M Merritt; Alpa M Nick; Amy R Carroll; Chunhua Lu; Koji Matsuo; Melissa Dumble; Nicholas Jennings; Shuyun Zhang; Yvonne G Lin; Whitney A Spannuth; Aparna A Kamat; Rebecca L Stone; Mian M K Shahzad; Robert L Coleman; Rakesh Kumar; Anil K Sood
Journal:  Mol Cancer Ther       Date:  2010-04-06       Impact factor: 6.261

4.  Targeted therapies: tailored treatment for ovarian cancer: are we there yet?

Authors:  Cristiana Sessa; Gianluca Del Conte
Journal:  Nat Rev Clin Oncol       Date:  2010-02       Impact factor: 66.675

Review 5.  Host factors and cancer progression: biobehavioral signaling pathways and interventions.

Authors:  Susan K Lutgendorf; Anil K Sood; Michael H Antoni
Journal:  J Clin Oncol       Date:  2010-07-19       Impact factor: 44.544

6.  Foretinib (GSK1363089), an orally available multikinase inhibitor of c-Met and VEGFR-2, blocks proliferation, induces anoikis, and impairs ovarian cancer metastasis.

Authors:  Marion Zillhardt; Sun-Mi Park; Iris L Romero; Kenjiro Sawada; Anthony Montag; Thomas Krausz; S Diane Yamada; Marcus E Peter; Ernst Lengyel
Journal:  Clin Cancer Res       Date:  2011-05-06       Impact factor: 12.531

7.  Phase I clinical trials in 85 patients with gynecologic cancer: the M. D. Anderson Cancer Center experience.

Authors:  John Moroney; Jennifer Wheler; David Hong; Aung Naing; Gerald Falchook; Diane Bodurka; Robert Coleman; Karen Lu; Lianchun Xiao; Razelle Kurzrock
Journal:  Gynecol Oncol       Date:  2010-03-26       Impact factor: 5.482

Review 8.  Beyond chemotherapy: targeted therapies in ovarian cancer.

Authors:  Timothy A Yap; Craig P Carden; Stan B Kaye
Journal:  Nat Rev Cancer       Date:  2009-03       Impact factor: 60.716

9.  Targeting pericytes with a PDGF-B aptamer in human ovarian carcinoma models.

Authors:  Chunhua Lu; Mian M K Shahzad; Myrthala Moreno-Smith; Yvonne G Lin; Nicholas B Jennings; Julie K Allen; Charles N Landen; Lingegowda S Mangala; Guillermo N Armaiz-Pena; Rosemarie Schmandt; Alpa M Nick; Rebecca L Stone; Robert B Jaffe; Robert L Coleman; Anil K Sood
Journal:  Cancer Biol Ther       Date:  2010-02-16       Impact factor: 4.742

10.  Selective blockade of matrix metalloprotease-14 with a monoclonal antibody abrogates invasion, angiogenesis, and tumor growth in ovarian cancer.

Authors:  Rajani Kaimal; Raid Aljumaily; Sarah L Tressel; Rutika V Pradhan; Lidija Covic; Athan Kuliopulos; Corrine Zarwan; Young B Kim; Sheida Sharifi; Anika Agarwal
Journal:  Cancer Res       Date:  2013-02-19       Impact factor: 12.701
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.